Literature DB >> 12620410

MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice.

Chi Wai So1, Holger Karsunky, Emmanuelle Passegué, Antonio Cozzio, Irving L Weissman, Michael L Cleary.   

Abstract

A specific association with mixed lineage leukemias suggests that MLL oncoproteins may selectively target early multipotent hematopoietic progenitors or stem cells. We demonstrate here that a representative MLL fusion protein, MLL-GAS7, impairs the differentiation and enhances the in vitro growth of murine hematopoietic cells with multipotent features. The multilineage differentiation potential of these cells was suggested by their immuno-phenotypes and transcriptional programs and confirmed by their ability to induce three pathologically distinct leukemias in mice, including an acute biphenotypic leukemia (ABL) that recapitulates the distinctive hallmark features of many MLL-associated leukemias in humans. This experimental modeling of ABL in mice highlights its origin from multipotential progenitors that arrest at a bipotential stage specifically targeted or induced by MLL oncogenes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620410     DOI: 10.1016/s1535-6108(03)00019-9

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  68 in total

1.  MLL-ENL leukemia burden initiated in femoral diaphysis and preceded by mature B-cell depletion.

Authors:  Agnieszka Jaracz-Ros; Daniel Lewandowski; Vilma Barroca; Catherine Lavau; Paul-Henri Roméo
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors.

Authors:  Antonio Cozzio; Emmanuelle Passegué; Paul M Ayton; Holger Karsunky; Michael L Cleary; Irving L Weissman
Journal:  Genes Dev       Date:  2003-12-15       Impact factor: 11.361

3.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.

Authors:  Paul M Ayton; Michael L Cleary
Journal:  Genes Dev       Date:  2003-09-02       Impact factor: 11.361

4.  Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis.

Authors:  Man Mohan; Chengqi Lin; Erin Guest; Ali Shilatifard
Journal:  Nat Rev Cancer       Date:  2010-09-16       Impact factor: 60.716

Review 5.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

6.  Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.

Authors:  Juhua Zhou; Mark E Dudley; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2005 Jan-Feb       Impact factor: 4.456

7.  Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.

Authors:  Sangho Park; Wei Chen; Tomasz Cierpicki; Marco Tonelli; Xiongwei Cai; Nancy A Speck; John H Bushweller
Journal:  Blood       Date:  2009-02-09       Impact factor: 22.113

Review 8.  Epigenetic alterations in hematopoietic malignancies.

Authors:  Young Rock Chung; Emma Schatoff; Omar Abdel-Wahab
Journal:  Int J Hematol       Date:  2012-09-27       Impact factor: 2.490

Review 9.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

10.  Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.

Authors:  Weili Chen; Ashish R Kumar; Wendy A Hudson; Quanzhi Li; Baolin Wu; Rodney A Staggs; Erik A Lund; Thien N Sam; John H Kersey
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.